Literature DB >> 14119519

USE OF AN ANION EXCHANGE RESIN IN TREATMENT OF TWO SIBLINGS WITH FAMILIAL HYPERCHOLESTEROLEMIA.

J M HORAN, N R DILUZIO, J N ETTELDORF.   

Abstract

Entities:  

Keywords:  ACID-BASE EQUILIBRIUM; ADOLESCENCE; BLOOD CHEMICAL ANALYSIS; BLOOD CHOLESTEROL; BLOOD LIPIDS; CHILD; FATTY ACIDS; GLYCERIDES; HYPERLIPEMIA, ESSENTIAL FAMILIAL; ION EXCHANGE RESINS; PHOSPHOLIPIDS

Mesh：

Substances：

Year:  1964        PMID： 14119519     DOI： 10.1016/s0022-3476(64)80263-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Effect of bile on Vibrio parahaemolyticus.

Authors:  J L Pace; T J Chai; H A Rossi; X Jiang
Journal:  Appl Environ Microbiol       Date:  1997-06       Impact factor: 4.792

2.  Use of cholestyramine in treatment of children with familial hypercholesterolaemia.

Authors:  R J West; J K Lloyd
Journal:  Arch Dis Child       Date:  1973-05       Impact factor: 3.791

3.  Disorders of the serum lipoproteins. II. Hyperlipoproteinaemic states.

Authors:  J K Lloyd
Journal:  Arch Dis Child       Date:  1968-10       Impact factor: 3.791

4.  Mutants, hyperlipoproteinaemia, and coronary artery disease.

Authors:  D S Fredrickson
Journal:  Br Med J       Date:  1971-04-24

5.  [Contribution to the problems of familial hypercholesteremic xanthomatosis].

Authors:  N Simon; N Tóth; J Jezerniczky
Journal:  Arch Klin Exp Dermatol       Date:  1965-12-01

6.  The effect of oral calcium carbonate administration on serum lipoproteins of children with familial hypercholesterolaemia (type II-A).

Authors:  P H Groot; W F Grose; R Dijkhuis-Stoffelsma; J Fernandes; J J Ambagtsheer
Journal:  Eur J Pediatr       Date:  1980-10       Impact factor: 3.183

7.  Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient.

Authors:  R B Moore; C A Crane; I D Frantz
Journal:  J Clin Invest       Date:  1968-07       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.